SEC Form 4 · accession 0001209191-18-057797
Adamas Pharmaceuticals Inc · ADMS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gregory T Went
Officer — Chief Executive Officer · Director
Period of report
Nov 7, 2018
Accepted (ET)
Nov 8, 2018 · 6:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001328143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 7, 2018 | P | 3,850 | $12.9757 | A | 199,242 | I | By Trust |
| Common Stock | holding | — | — | — | 182,610 | D |
Table II — derivative securities
No Table II lines on this filing.
Remarks
The shares previously reported by the reporting person as held for the benefit of the reporting person's children through trusts are no longer being reported as being indirectly beneficially owned by the reporting person since the the children are adults not living in the same household.